High ‘Cholera Sell’? Vouching for Paxvax’s Phase III Strategy
Paxvax Inc.’s just-begun Phase III effort with PXVX0200 could lead to the first cholera vaccine approved for marketing in the U.S., and the company could become the first to gauge the resale value of the FDA’s priority review voucher (PRV), an incentive put in place six years ago to boost work against neglected tropical diseases.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST